First-line pembrolizumab plus chemotherapy for extensive-stage small-cell lung cancer: a United States-based cost-effectiveness analysis

Abstract Background The clinical trial of Keynote-604 showed that pembrolizumab plus chemotherapy could generate clinical benefits for extensive-stage small-cell lung cancer (ES-SCLC). We aim to assess the efficacy and cost of pembrolizumab combined with chemotherapy in the first-line treatment sett...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Youwen Zhu, Huabin Hu, Dong Ding, Shuosha Li, Mengting Liao, Yin Shi, Jin Huang
Formato: article
Lenguaje:EN
Publicado: BMC 2021
Materias:
Acceso en línea:https://doaj.org/article/fae3fec1da7f4facb34e366107f698eb
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!